Shots:
- Baxter to acquire Hillrom for $156.00/ share in cash making a total equity value of ~$10.5B representing a premium of 26% to the stock’s closing price of $124 and a total enterprise value of ~ $12.4B, including the assumption of debt. The acquisition is expected to be closed in early 2022
- The acquisition will expand access to Hillrom’s portfolio globally and accelerate the companies’ expansion into digital and connected care solutions at home or in other care settings
- Baxter to get a broader array of medical products and services to patients and clinicians across the continuum of care. The companies expect about $250M in annual cost synergies over the next three yrs.
Click here to read full press release/ article | Ref: Businesswire | Image: Baxter
The post Baxter to Acquire Hillrom for ~$10.5B first appeared on PharmaShots.
